Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023 Wellness brand Elixinol will sell off non-core assets and aim to unlock “restricted cash” as it […]
Neurotech reports positive results from latest trial of cannabinoid drug candidate NTI164 by Martin Lane October 6, 2023April 30, 2024
Company news: Vantage Hemp; Neurotech International; MediPharm Labs/Beacon Medical; Cann Group by Martin Lane September 28, 2023April 30, 2024
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: MGC Pharma; Neurotech International; Incannex Healthcare by Martin Lane June 1, 2023April 30, 2024
Company news: Medicinal Harvest; Cannasouth/Eqalis; Cann Group; MGC Pharma; Incannex; Neurotech by Martin Lane May 3, 2023April 30, 2024
Company news: Neurotech; Emyria; InhaleRx by Martin Lane and Steve Jones March 23, 2023April 30, 2024
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023
Company news: Neurotech; Emyria; Cann Group; Incannex; Creso Pharma; Greenfern; Zelira; Organic Genetics by Martin Lane November 24, 2022April 29, 2024
